VRTX News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

VR

Mkt Cap

$127.62B

Volume

475.66K

Next Earnings

November 2nd

Chart Earnings News About Insider Filings

Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?Novavax stock jumped 20.1% following renewed investor interest in vaccine stocks, triggered by pneumonia-related concerns in Russia and positive results from Vaxcyte's pneumococcal vaccine. The company benefits from COVID-19 vaccine approvals and a Sanofi partnership. However, Novavax faces declining revenues and continued quarterly losses, though earnings estimate revisions have improved significantly.Zacks Investment Research · Oct 6, 2026

Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to KnowVertex Pharmaceuticals stock declined 3.07% to $506.74 on October 1, 2026, underperforming the broader market gains. Despite positive earnings forecasts with expected EPS growth of 1.25% and revenue growth of 10.43% for the upcoming quarter, the stock has fallen 6.1% over the past month. The company holds a Zacks Rank of #3 (Hold) with a Forward P/E ratio of 27.73, trading at a premium to its industry average.Zacks Investment Research · Oct 1, 2026

Vertex Posts Positive Phase II Data on Kidney Disease DrugVertex Pharmaceuticals reported positive results from its phase IIb AMPLIFIED study, showing that inaxaplin reduced UACR by 42.7% in AMKD patients with modest proteinuria and 17.3% in those with AMKD and type II diabetes. The company has completed enrollment in the phase II/III AMPLITUDE pivotal study, with interim data expected in early 2027. Inaxaplin was well-tolerated with no serious adverse events reported.Zacks Investment Research · Sep 23, 2026

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYHThe Invesco Nasdaq Biotechnology ETF (IBBQ) offers lower costs (0.19% expense ratio) and higher 1-year returns (44.6%), making it suitable for growth-focused investors willing to accept volatility. The iShares U.S. Healthcare ETF (IYH) provides broader diversification across 100 healthcare holdings with higher dividend yield (1.1%) and lower volatility, appealing to conservative investors seeking stability and income.The Motley Fool · Sep 23, 2026

Aerska Appoints Laura Sepp-Lorenzino to Scientific Advisory BoardAerska, a biotechnology company developing RNA medicines for CNS diseases through its antibody-oligonucleotide conjugate (AOC) platform, has appointed Laura Sepp-Lorenzino to its Scientific Advisory Board. Sepp-Lorenzino brings over 30 years of experience in genetic medicines and nucleic acid therapies, previously serving as Chief Scientific Officer at Intellia Therapeutics and leading nucleic acid programs at Vertex Pharmaceuticals.GlobeNewswire Inc. · Sep 17, 2026

SION to Cut Workforce by Nearly Half After CF Study Failure, Stock DownSionna Therapeutics announced a 46% workforce reduction and major restructuring following the failure of SION-719 to meet its primary endpoint in a cystic fibrosis study. The company is shifting focus to its dual combination therapy SION-451 + SION-2222, which it plans to advance into phase IIa trials in 2027. The restructuring is expected to extend cash runway into the second half of 2029.Zacks Investment Research · Sep 16, 2026

My Top 5 Favorite Stocks for an Uncertain MarketThe article recommends five resilient stocks suitable for uncertain market conditions: Johnson & Johnson (pharmaceutical and medtech leader with 28 billion-dollar products), Vertex Pharmaceuticals (cystic fibrosis treatment market leader with pipeline expansion), Costco (essential goods retailer with high membership renewal rates), Coca-Cola (beverage company with strong brands and free cash flow), and American Express (payment card company with affluent customer base). These companies offer stability through essential products, strong market positions, and consistent dividend payments.The Motley Fool · Sep 16, 2026

Should You Invest in the VanEck Biotech ETF (BBH)?The VanEck Biotech ETF (BBH) offers low-cost exposure to the biotech sector with a 0.35% expense ratio and $462.7 million in assets. The fund tracks the MVIS US Listed Biotech 25 Index and holds 26 companies with top holdings including Amgen, Gilead Sciences, and Vertex Pharmaceuticals. BBH has returned 21.89% year-to-date and 39.46% over the past year, but carries higher risk with a beta of 0.70 and 19.89% standard deviation. The fund received a Zacks ETF Rank of 2 (Buy).Zacks Investment Research · Sep 16, 2026

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The article compares AbbVie, a mature pharmaceutical company with stable cash flows and a growing immunology portfolio, against CRISPR Therapeutics, a clinical-stage biotech firm pioneering gene-editing therapies. AbbVie is recommended as the better choice for 2026 due to its profitability, strong free cash flow generation, and rising dividend, while CRISPR offers high-reward potential but faces significant cash burn and execution risks.The Motley Fool · Sep 14, 2026

Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The article compares Amgen, an established pharmaceutical giant with $36.7B in revenue and a 2.60% dividend yield, against CRISPR Therapeutics, a gene-editing biotech pioneer with only $3.5M in revenue but groundbreaking CASGEVY therapy. While CRISPR offers high-growth potential, it remains unprofitable with significant losses. The author recommends Amgen for most investors seeking stability and predictable returns, though acknowledges CRISPR's improving commercial trajectory makes it a more compelling speculative opportunity than previously.The Motley Fool · Sep 11, 2026

VR

VRTXVertex Pharmaceuticals Inc

VRTX

Pay with—

Available Balance0.00

Your PositionYou don't own any VRTX yet.

Related Tickers

Earnings